{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:44:59Z","timestamp":1772012699069,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,6,9]],"date-time":"2006-06-09T00:00:00Z","timestamp":1149811200000},"content-version":"vor","delay-in-days":830,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction Biology"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to assess blood free naltrexone and 6\u2010\u03b2\u2010naltrexol levels with time following treatment with sequential sustained\u2010release naltrexone preparations. Data were collected from blood samples analysed independently for naltrexone and 6\u2010\u03b2\u2010naltrexol and from clinical record review at a community heroin treatment clinic in Perth, Western Australia. Five patients received sequential 3.4 g (3.49\u200a?\u200a0.01 g and 3.36\u200a?\u200a0.05 g, respectively) naltrexone implants. The second implant was received on average within 131.2\u200a?\u200a15.67 days of the first implant. The mean length of follow\u2010up was 307.2\u200a?\u200a18.28 days of the first implant. Blood naltrexone levels have the potential to remain above 2 and 1 ng\/ml for a total of 390 and 524 days, respectively, and blood 6\u2010\u03b2\u2010naltrexol was maintained above 10 ng\/ml for a total of 222 days following insertion of these implants. No patient relapsed to dependent heroin use during the implant coverage period while blood naltrexone concentrations were above 2 ng\/ml. Results indicate that blood naltrexone and 6\u2010\u03b2\u2010naltrexol levels can be maintained above therapeutic levels for prolonged periods following use of sequential 3.4 g naltrexone implants. These extended periods of coverage will offer significant benefits for managing the heroin\u2010dependent patient.<\/jats:p>","DOI":"10.1080\/13556210410001674112","type":"journal-article","created":{"date-parts":[[2004,4,21]],"date-time":"2004-04-21T14:29:37Z","timestamp":1082557777000},"page":"67-72","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Achieving long\u2010term continuous blood naltrexone and 6\u2010\u00df\u2010naltrexol coverage following sequential naltrexone implants"],"prefix":"10.1111","volume":"9","author":[{"given":"GK","family":"Hulse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DE","family":"Arnold\u2010Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"O'Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u2010T","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RC","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,6,9]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"42","article-title":"Clinical experience with naltrexone in suburban opioid addicts","volume":"45","author":"Tennant FS","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(81)90110-1"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1300\/J069v13n01_04"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1999.tb123493.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595230096138"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1991.tb01859.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0160-3450(16)31736-6"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(85)90076-6"},{"key":"e_1_2_1_10_2","first-page":"260","article-title":"Naltrexone implants for opiate addiction: new life for a middle aged drug","volume":"267","author":"Brewer C","year":"2001","journal-title":"Pharm J"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100909"},{"key":"e_1_2_1_12_2","first-page":"704","article-title":"Kinetics of a naltrexone sustained\u2010release preparation","volume":"36","author":"Chiang CN","year":"1984","journal-title":"Clin Pharmacol The"},{"key":"e_1_2_1_13_2","unstructured":"VerebyKThe clinical pharmacology of naltrexone: pharmacology and pharmacodynamics1980;147\u201358In:Barnett REWAG editor.Naltrexone. Research Monograph no. 28."},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/13556210410001674103"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/13556210220139541"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976203315"},{"key":"e_1_2_1_17_2","unstructured":"BuggeCJL GrunI StanforK TanMS GarciaDBDetermination of naltrexone and 6\u2010\u03b2\u2010naltrexol in human plasma by LC\u2010MS\u2010MS1996Available at:http:\/\/www.cedracorp.com\/naltrex.htm."},{"key":"e_1_2_1_18_2","first-page":"672","article-title":"Implantable narcotic antagonists: a possible new treatment for narcotic addiction","volume":"21","author":"Chiang CN","year":"1985","journal-title":"Psychopharmacol Bul"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1197\/aemj.9.1.63"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00098-2"},{"key":"e_1_2_1_21_2","volume-title":"Blood naltrexone and 6\u2010\u03b2\u2010naltrexol levels following naltrexone implant: a comparison of two brands Paper presented at the the 7th International Stapleford Conference","author":"Hulse GK","year":"2002"}],"container-title":["Addiction Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1080%2F13556210410001674112","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/13556210410001674112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T21:54:10Z","timestamp":1700171650000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/13556210410001674112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1080\/13556210410001674112"],"URL":"https:\/\/doi.org\/10.1080\/13556210410001674112","archive":["Portico"],"relation":{},"ISSN":["1355-6215","1369-1600"],"issn-type":[{"value":"1355-6215","type":"print"},{"value":"1369-1600","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]},"assertion":[{"value":"2006-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}